TICKERNERD
Menu
RGCRGCHealthcare · Drug Manufacturers - Specialty & Generic

RGC Stock Forecast: Regencell Bioscience Holdings Ltd. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$7.35
+1.52% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 6 Oct 2026 — in the weakest quartile.

Market cap
$3.4B
Ticker Nerd rank
4 / 100
Median analyst target
—
Analysts covering
15
Total return, dividends reinvested
1W
+18.5%
1M
+6.7%
YTD
−65.0%
1Y
−57.4%
From 52W high
−86.1%
From 52W low
+53.8%
$5
$53
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RGC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regencell Bioscience Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
35
Issuance
34
Volatility
29
Size
27
Revisions
25
Accruals
17
Value
17
Momentum
17
Quality
6

Growth (35): Sales and profits are climbing, and climbing faster than before.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RGC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RGC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26RGC

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
9 Buy5 Hold1 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 Dec 2017MacquarieDowngradeNeutral—
6 Dec 2017MoffettNathansonUpgradeNeutral—
6 Dec 2017RBC CapitalDowngradeSector Perform—
5 Dec 2017WedbushDowngradeNeutral—
26 Oct 2017RBC CapitalUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RGC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RGC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, Regencell Bioscience Holdings Ltd. returned −57.4% against +17.3% for the S&P 500, dividends included.

RGC vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250Jan 26Apr 26Jul 26Oct 26RGCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RGC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Regencell Bioscience Holdings Ltd. (RGC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1001.4×

Cheaper than 99% of US stocks

Price / sales
—
Price / book
3565.0×

Cheaper than 1% of US stocks

EV / EBITDA
−477.0×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−177.7%

Higher than 8% of US stocks

Return on assets
−85.0%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Regencell Bioscience Holdings Ltd. (RGC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Regencell Bioscience Holdings Ltd. has a market value of $3.4B and an enterprise value of $3.4B.

  • Shares outstanding: 494.5M.

  • Trailing P/E: −1001.4×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Regencell Bioscience Holdings Ltd. employs 10 people.

market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

RGC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
RGCRegencell Bioscience Holdings Ltd.$3.4B
4
AMLXAmylyx Pharmaceuticals, Inc.$3.5B
59
INDVIndivior Pharmaceuticals, Inc.$4.2B
97
SUPNSupernus Pharmaceuticals, Inc.$2.5B
80
ALVOAlvotech$2.4B
31
LQDALiquidia Corp.$2.3B
70
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regencell Bioscience Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RGC news & analysis

RGC Resources: More Likely To Appeal More To Income-Focused Investors

Seeking Alpha · 18 Aug 2026neutral

Seeking Alpha published an analysis of RGC Resources, a micro-cap natural gas utility with limited growth prospects and a small, stable service area. The article notes sluggish earnings growth, with FY 2026 guidance implying just 1.2% year-over-year EPS growth, and highlights a 4.04% forward dividend yield supported by an 82-year dividend history.

Why it matters — RGC watchers would care because the piece frames the company as primarily appealing to income-focused investors given its long dividend history, while acknowledging its limited growth outlook.

FAQ

Frequently asked questions about RGC stock

Is RGC stock a buy right now?

Of the 15 analysts covering Regencell Bioscience Holdings Ltd., 9 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Regencell Bioscience Holdings Ltd. 4 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RGC?

As at 6 Oct 2026, Regencell Bioscience Holdings Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (35 of 100).

What is the RGC stock forecast for 2030?

No analyst covering Regencell Bioscience Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RGC are extrapolating price history, which says nothing about the business.

How has RGC stock performed over the past year?

Regencell Bioscience Holdings Ltd. returned -57.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regencell Bioscience Holdings Ltd. do?

Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine-based products. Regencell Bioscience Holdings Limited concentrates on treatments for neurocognitive disorders and degeneration, with particular attention to attention deficit hyperactivity disorder and autism spectrum disorder.

What is the latest news on RGC?

The most recent item we track (Seeking Alpha, 18 Aug 2026): "RGC Resources: More Likely To Appeal More To Income-Focused Investors". Seeking Alpha published an analysis of RGC Resources, a micro-cap natural gas utility with limited growth prospects and a small, stable service area. The article notes sluggish earnings growth, with FY 2026 guidance implying just 1.2% year-over-year EPS growth, and highlights a 4.04% forward dividend yield supported by an 82-year dividend history.

Company

About Regencell Bioscience Holdings Ltd.

Regencell Bioscience Holdings Limited is an early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine-based products. Regencell Bioscience Holdings Limited concentrates on treatments for neurocognitive disorders and degeneration, with particular attention to attention deficit hyperactivity disorder and autism spectrum disorder. The company also applies its bioscience platform to infectious diseases that affect the immune system, reflecting a broader therapeutic scope within natural and holistic healthcare. Its product development approach centers on standardized TCM formulations designed for clinical use, positioning the company within the specialty biopharmaceutical segment of the health technology market. Regencell Bioscience Holdings Limited serves as a niche participant in the medical and pharmaceutical landscape by targeting conditions with unmet treatment needs through non-conventional medicine-based research and commercialization.

CEO Mr. Yat-Gai Au · 10 employees · Hong Kong · https://www.regencellbioscience.com